|
|
Article: Isotron enters license agreement to market neutron brachytherapy.
- Article from:
- Obesity, Fitness & Wellness Week
- Article date:
- December 25, 2004
CopyrightCOPYRIGHT 2004 NewsRX. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
2004 DEC 25 - (NewsRx.com & NewsRx.net) -- Isotron and UT-Battelle, which manages Oak Ridge National Laboratory (ORNL), have signed a license agreement that allows Isotron to market a treatment called neutron brachytherapy, which enables physicians to deliver a highly concentrated dose of californium-252 neutrons to the site of a tumor instead of having to treat the tumor with conventional gamma rays.
"This new procedure could be used to more effectively treat literally thousands of patients with cancer, including brain tumors, some of which today have 5-year survival rates of less than 1%," said Manfred Sandler, a cardiologist and chief executive officer of ...